199 related articles for article (PubMed ID: 23963056)
1. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
[TBL] [Abstract][Full Text] [Related]
2. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
[TBL] [Abstract][Full Text] [Related]
3. Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence.
Samochowiec J; Kucharska-Mazur J; Grzywacz A; Jabłoński M; Rommelspacher H; Samochowiec A; Sznabowicz M; Horodnicki J; Sagan L; Pełka-Wysiecka J
Neurosci Lett; 2006 Dec; 410(1):1-5. PubMed ID: 17079080
[TBL] [Abstract][Full Text] [Related]
4. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl ML
Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
Matsumoto C; Shinkai T; Hori H; Ohmori O; Nakamura J
Psychiatry Res; 2004 Jun; 127(1-2):1-7. PubMed ID: 15261699
[TBL] [Abstract][Full Text] [Related]
7. Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET).
Rybakowski JK; Borkowska A; Czerski PM; Dmitrzak-Weglarz M; Skibinska M; Kapelski P; Hauser J
Psychiatry Res; 2006 Jun; 143(1):13-9. PubMed ID: 16712949
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis.
Huang E; Zai CC; Lisoway A; Maciukiewicz M; Felsky D; Tiwari AK; Bishop JR; Ikeda M; Molero P; Ortuno F; Porcelli S; Samochowiec J; Mierzejewski P; Gao S; Crespo-Facorro B; Pelayo-Terán JM; Kaur H; Kukreti R; Meltzer HY; Lieberman JA; Potkin SG; Müller DJ; Kennedy JL
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26745992
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence.
Vereczkei A; Demetrovics Z; Szekely A; Sarkozy P; Antal P; Szilagyi A; Sasvari-Szekely M; Barta C
PLoS One; 2013; 8(6):e66592. PubMed ID: 23840506
[TBL] [Abstract][Full Text] [Related]
10. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
[TBL] [Abstract][Full Text] [Related]
11. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity.
Kotler M; Barak P; Cohen H; Averbuch IE; Grinshpoon A; Gritsenko I; Nemanov L; Ebstein RP
Am J Med Genet; 1999 Dec; 88(6):628-33. PubMed ID: 10581481
[TBL] [Abstract][Full Text] [Related]
12. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients.
Nakazono Y; Abe H; Murakami H; Koyabu N; Isaka Y; Nemoto Y; Murata S; Tsutsumi Y; Ohtani H; Sawada Y
Int J Clin Pharmacol Ther; 2005 Apr; 43(4):163-71. PubMed ID: 15966462
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase gene Val108/158Met polymorphism, and susceptibility to schizophrenia: association is more significant in women.
Sazci A; Ergul E; Kucukali I; Kilic G; Kaya G; Kara I
Brain Res Mol Brain Res; 2004 Dec; 132(1):51-6. PubMed ID: 15548428
[TBL] [Abstract][Full Text] [Related]
14. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia.
Ohnishi T; Hashimoto R; Mori T; Nemoto K; Moriguchi Y; Iida H; Noguchi H; Nakabayashi T; Hori H; Ohmori M; Tsukue R; Anami K; Hirabayashi N; Harada S; Arima K; Saitoh O; Kunugi H
Brain; 2006 Feb; 129(Pt 2):399-410. PubMed ID: 16330500
[TBL] [Abstract][Full Text] [Related]
15. [Associations between six functional genes and schizophrenia].
Zhang ML; Yuan GZ; Yao JJ; Qian YC; Zhang X; Huang YP; Tang RC; Ji Q; Jiang SD
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb; 20(1):69-71. PubMed ID: 12579508
[TBL] [Abstract][Full Text] [Related]
16. COMT polymorphisms and anxiety-related personality traits.
Stein MB; Fallin MD; Schork NJ; Gelernter J
Neuropsychopharmacology; 2005 Nov; 30(11):2092-102. PubMed ID: 15956988
[TBL] [Abstract][Full Text] [Related]
17. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability.
Xu H; Kellendonk CB; Simpson EH; Keilp JG; Bruder GE; Polan HJ; Kandel ER; Gilliam TC
Schizophr Res; 2007 Feb; 90(1-3):104-7. PubMed ID: 17113268
[TBL] [Abstract][Full Text] [Related]
18. Association of DRD2, DRD4 and COMT genes variants and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia.
Taheri N; Pirboveiri R; Sayyah M; Bijanzadeh M; Ghandil P
BMC Psychiatry; 2023 Oct; 23(1):781. PubMed ID: 37880658
[TBL] [Abstract][Full Text] [Related]
19. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia.
Lai IC; Wang YC; Lin CC; Bai YM; Liao DL; Yu SC; Lin CY; Chen JY; Liou YJ
J Neural Transm (Vienna); 2005 Aug; 112(8):1107-13. PubMed ID: 15583953
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
